Boehringer Ingelheim Oncology
Cancer takes. Takes away time. Takes away loved ones. At Boehringer Ingelheim Oncology, we are giving patients new hope, by taking cancer on. We are collaborating with the oncology community to deliver treatment breakthroughs that can transform the lives of patients. We are leading scientific discoveries in cancer cell-directed agents, immuno-oncology therapies and combination approaches, primarily in lung and gastrointestinal cancers, to complement our existing products. Our goal is delivering first-in-class treatments with breakthrough potential.
ESMO Virtual Congress 2020 Industry Satellite Symposium
Focus on NSCLC treatment options
Treatments after progression in the first-line of non-mutated non-small cell lung cancer (NSCLC) adenocarcinoma
Uncommon EGFR mutations
The future of NSCLC
Q & A
Key insights and closing remarks
ESMO Asia Virtual Congress 2020 Industry Satellite Symposium
Treatment considerations for advanced NSCLC: now and in the future
Navigating first-line treatment decisions for EGFRM+ NSCLC: Extrapolating from Asian clinical trial experience
John Wen-Cheng Chang
Tackling Uncommon EGFR mutations: Efficacy of EGFR TKIs in NSCLC
KRAS-mutant NSCLC treatment advances on the horizon
- Live Q&A
To find out more about our ongoing collaborations, approved and investigational compounds, oncology meetings, congresses, symposia and other activities sponsored by Boehringer Ingelheim, visit: www.inoncology.com.
Boehringer Ingelheim has produced educational slide decks covering topics such as the epidemiology, diagnosis and treatment of various lung and gastrointestinal cancers, as well as overviews of a range of therapeutic strategies in cancer. Visit the inOncology.com slide bank to explore these materials.